GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArcticZymes Technologies ASA (LTS:0DRV) » Definitions » Debt-to-EBITDA

ArcticZymes Technologies ASA (LTS:0DRV) Debt-to-EBITDA : -0.98 (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is ArcticZymes Technologies ASA Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

ArcticZymes Technologies ASA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr3.7 Mil. ArcticZymes Technologies ASA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr5.2 Mil. ArcticZymes Technologies ASA's annualized EBITDA for the quarter that ended in Sep. 2024 was kr-9.1 Mil. ArcticZymes Technologies ASA's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -0.98.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for ArcticZymes Technologies ASA's Debt-to-EBITDA or its related term are showing as below:

LTS:0DRV' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.11   Med: 0.28   Max: 3.07
Current: 0.64

During the past 13 years, the highest Debt-to-EBITDA Ratio of ArcticZymes Technologies ASA was 3.07. The lowest was -2.11. And the median was 0.28.

LTS:0DRV's Debt-to-EBITDA is ranked better than
61.85% of 270 companies
in the Biotechnology industry
Industry Median: 1.41 vs LTS:0DRV: 0.64

ArcticZymes Technologies ASA Debt-to-EBITDA Historical Data

The historical data trend for ArcticZymes Technologies ASA's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArcticZymes Technologies ASA Debt-to-EBITDA Chart

ArcticZymes Technologies ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.07 0.23 0.28 0.29 0.40

ArcticZymes Technologies ASA Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.28 1.17 0.94 -0.98

Competitive Comparison of ArcticZymes Technologies ASA's Debt-to-EBITDA

For the Biotechnology subindustry, ArcticZymes Technologies ASA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ArcticZymes Technologies ASA's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArcticZymes Technologies ASA's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ArcticZymes Technologies ASA's Debt-to-EBITDA falls into.



ArcticZymes Technologies ASA Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

ArcticZymes Technologies ASA's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.174 + 8.414) / 31.644
=0.40

ArcticZymes Technologies ASA's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.72 + 5.211) / -9.076
=-0.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


ArcticZymes Technologies ASA  (LTS:0DRV) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


ArcticZymes Technologies ASA Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ArcticZymes Technologies ASA's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


ArcticZymes Technologies ASA Business Description

Traded in Other Exchanges
Address
Sykehusveien 23, Tromso, NOR, 9294
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Germany, Italy, France, and other countries.

ArcticZymes Technologies ASA Headlines

No Headlines